Tarsier Pharma
Haifa
About Tarsier Pharma
Tarsier Pharma is a late clinical-stage company dedicated to the development and commercialization of a breakthrough therapeutic approach for better and safer treatment of autoimmune and inflammatory ocular diseases. The TRS Platform Technology is a bio-inspired immunomodulator designed to treat blinding inflammatory ocular diseases and is currently being developed as both eye drops and intravitreal injections. Ocular inflammations are a group of diseases affecting the front and back of the eye. Non-infectious anterior and posterior uveitis is the most known ocular inflammatory disease. However, ocular inflammation is a critical underlying mechanism in the pathology of other inflammatory eye diseases, such as non-evaporative dry eye, diabetic macular edema (DME), and dry age-related macular degeneration (AMD). Hundreds of millions of people in all age groups are suffering from ocular inflammatory diseases worldwide, conditions that pose severe risks of vision loss and blindness.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $5.4M
- Last round: Grant (Sep 2019)
- Website: tarsiuspharma.com
- Phone: [email protected]
Industries & Categories
Biopharma, Medical, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/tarsier-pharma-108734 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.